Meeting
2021 Genitourinary Cancers Symposium
Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.
Authors
Landon Carter Brown
Duke Cancer Institute, Durham, NC
Landon Carter Brown , Susan Halabi , Michael Sandon Humeniuk , Yuan Wu , Taofik Oyekunle , Jiaoti Huang , Monika Anand , Catrin Davies , Tian Zhang , Michael Roger Harrison , Daniel J. George , Andrew J. Armstrong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03179410
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 89)
DOI
10.1200/JCO.2021.39.6_suppl.89
Abstract #
89
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Jodi Lyn Layton
Poster
2024 ASCO Genitourinary Cancers Symposium
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
First Author: Xiao X. Wei
Poster
2021 Genitourinary Cancers Symposium
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.
First Author: Adam Kessel
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova